Applications
Allergic Diseases
Mast cell hyperactivation plays a causal role in many allergic and inflammatory diseases. Many of these diseases have no or very limited treatment alternatives with severe side effects.
With RAFT intervention therapeutics, JADO introduces a new mode-of-action for the treatment of moderate to severe cases of allergic diseases. These compounds are positioned to replace steroids and immunosuppressive agents, such as Cyclosporin® and Tacrolimus®, in topical allergy treatment, and immunosuppressants in systemic treatment of moderate to severe allergy.
The incidence of allergy and asthma is rising dramatically. More than one million Americans suffer from atopic dermatitis or urticaria (hives), forty million from allergic rhinitis (hay fever) and 10 million from asthma. In the US alone, $1 billion is spent on antihistamines and the global asthma/COPD market is approximately $13 billion. Many of the currently available therapies are inadequate and the patients’ quality of life is severely reduced. There is a strong demand for therapies with improved profiles and new modes-of-action to supplement existing therapies or to establish a new line of defense against allergic diseases.
JADO is conducting phase II studies for its first-in-class allergy therapeutic, TF002, for topical treatment of cutaneous mastocytosis and atopic dermatitis. A systemic version of the compound is also being investigated.
|
|||||
